The results of the PROMINENT study were recently published in the NEJM

Unfortunately, adding pemafibrate to statin-treated diabetic patients with high triglycerides and low HDLC did not reduce cardiovascular risk further. Dr Blom from the Lipid Group at the Cape heart Institute was a member of the steering committee and the national co-ordinator for South Africa. Read the full paper here